Core Viewpoint - FOXO Technologies Inc. has announced the spin-off of its subsidiary FOXO Labs, Inc., which focuses on epigenetics, aiming to enhance business strategy and shareholder value [1][3]. Group 1: Company Overview - FOXO Technologies operates three subsidiaries, including Rennova Community Health, Inc. and Myrtle Recovery Centers, Inc., which provide healthcare services [4]. - FOXO Labs, Inc. is dedicated to improving human health and lifespan through advanced technology and product solutions [5]. Group 2: Epigenetics Business - FOXO Labs is a pioneer in integrating epigenetic biomarkers into underwriting protocols and consumer engagement tools, holding Patent No. 11,817,214 for a machine learning model that uses DNA epigenetic data [1]. - The epigenetic technology developed by FOXO Labs offers insights into health, lifestyle, and longevity from a single saliva sample, eliminating the need for invasive testing [2]. Group 3: Business Strategy and Future Plans - The CEO of FOXO Labs emphasized that the spin-off will create opportunities for a subscription-based revenue model focused on personal health and longevity [3]. - The spin-off strategy allows FOXO shareholders to directly own FOXO Labs while retaining some ownership, simplifying the business model for both entities [3].

Core Insights - FOXO Technologies Inc. announced that its subsidiary Myrtle Recovery Centers has been approved for a second year of funding from Scott County Opioid Abatement Funds to provide care for uninsured patients starting July 1, 2025 [1][2] - Myrtle Recovery Centers operates at full capacity with a waiting list, indicating strong demand for its services and the quality of care provided [2] - FOXO Technologies plans to expand Myrtle Recovery Centers through organic growth and acquisitions, anticipating significant revenue contributions in the future [2] Company Overview - FOXO Technologies operates three subsidiaries: Rennova Community Health, which runs Scott County Community Hospital, Myrtle Recovery Centers, a 30-bed behavioral health facility, and FOXO Labs, a biotechnology company focused on health and lifespan improvement [3][4] - Myrtle Recovery Centers provides inpatient detox and residential treatment, as well as outpatient services for Medication-Assisted Treatment (MAT) and Office-Based Opioid Treatment (OBOT) programs [3]

Core Points - FOXO Technologies Inc. has designated a new series of preferred stock, Series E Cumulative Redeemable Secured Preferred Stock, with a stated value of $25.00 per share and a 2.5% cash dividend paid semi-annually [1] - The Series E Preferred Stock will serve as both an acquisition currency and a capital raising security, aimed at supporting the company's acquisition strategy and enhancing long-term value for stockholders [2] - FOXO operates three subsidiaries, including a critical access hospital and a behavioral health facility, indicating its involvement in the healthcare sector [3] Financial Details - The Series E Preferred Stock includes a 5.0% per annum common stock dividend paid semi-annually and a security interest in the stock of FOXO's acquisition vehicle [1] - The company intends to publicly list the Series E Preferred Stock with its own trading symbol at an appropriate time [2] Company Overview - FOXO Technologies Inc. focuses on improving human health and lifespan through biotechnology and innovative product solutions [4] - The company operates in the healthcare industry, with subsidiaries that provide critical access healthcare and behavioral health services [3]

Core Insights - FOXO Technologies Inc. has announced the launch of wound care services at its critical access hospital, Big South Fork Medical Center, in Oneida, Tennessee, to meet the growing demand, particularly among diabetic patients [1][2] Group 1: Company Overview - FOXO Technologies Inc. operates three subsidiaries, including Rennova Community Health, which manages the Big South Fork Medical Center [3] - The company also owns Myrtle Recovery Centers, a behavioral health facility providing various treatment services [3] Group 2: Service Expansion - The expansion of wound care services is expected to increase net revenues for the hospital and is part of a broader strategy to enhance market reach and service offerings [2]

Core Viewpoint - FOXO Technologies Inc. has established a new wholly-owned subsidiary, FOXO Acquisition Corporation, aimed at acquiring targets in the healthcare services sector, while also planning to create a new series of non-convertible preferred stock to facilitate these acquisitions [1][2]. Group 1: Company Developments - On June 13, 2025, FOXO formed FOXO Acquisition Corporation in Florida to pursue targeted acquisitions [2]. - The company plans to issue a new series of non-convertible preferred stock, which is expected to be publicly listed and will generate cash and common stock dividends for investors [2]. - CEO Seamus Lagan expressed optimism about the acquisition strategy, emphasizing non-dilutive funding for common stockholders and targeting acquisitions with significant growth potential [3]. Group 2: Leadership Changes - The company announced the passing of Interim Chief Financial Officer Martin Ward on June 9, 2025, and Seamus Lagan has been appointed as the Interim CFO while a search for a permanent replacement is underway [4]. Group 3: Company Overview - FOXO operates three subsidiaries: Rennova Community Health, which runs a critical access hospital in East Tennessee; Myrtle Recovery Centers, a behavioral health facility; and FOXO Labs, a biotechnology company focused on health and lifespan improvement [6][7].

Core Viewpoint - FOXO Technologies Inc. has executed an agreement to issue 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock for net proceeds of $1,500,000, indicating a strategic move to enhance its financial position and support growth initiatives [1][2]. Financial Summary - The issuance of Series A Preferred Stock is expected to generate gross proceeds of $1,650,000, with the company agreeing to pay investor costs of $150,000 [2]. - The first closing of this transaction occurred on June 4, 2025, with subsequent closings planned based on the effective date of a registration statement [2]. - In the first quarter of 2025, FOXO reported over $3 million in net revenues and a $4.4 million improvement in stockholders' equity, bringing total stockholders' equity to $9.7 million as of March 31, 2025, compared to a negative $17.5 million as of September 30, 2024 [3]. Company Overview - FOXO Technologies operates three subsidiaries: Rennova Community Health, which runs a critical access hospital in East Tennessee; Myrtle Recovery Centers, a behavioral health facility; and FOXO Labs, a biotechnology company focused on health and lifespan improvement through innovative technology [4][5].

Business Segments - FOXO Technologies Inc. operates in two reportable business segments: Healthcare and Labs and Life, with a focus on behavioral health services and epigenetic diagnostics [205]. - The company finalized the acquisition of Myrtle and RCHI in 2024, expecting these businesses to produce a small cash flow surplus through 2025 [261]. Acquisitions - The company completed the acquisition of Myrtle for $0.5 million, which included a $0.3 million non-interest bearing note payable and 102,363 shares of Class A Common Stock [211]. - The company acquired RCHI and its subsidiary SCCH, with a senior secured note issued for $22.0 million, maturing on September 10, 2026, and accruing interest at rates of 8% to 20% [216][217]. - Myrtle's alcohol and drug treatment facility began operations on August 14, 2023, offering services for up to 30 patients, and expanded to include a Nonresidential Office-Based Opiate Treatment Facility on November 1, 2023 [213][224]. - The company plans to expand Myrtle's business model by acquiring additional facilities and replicating the model in other rural areas [224]. Financial Performance - Net revenues for the three months ended March 31, 2025, were $3.2 million, a significant increase from $7,180 for the same period in 2024, with contributions of $0.5 million from Myrtle and $2.7 million from RCHI [234]. - Direct costs of revenues were $1.9 million for the three months ended March 31, 2025, with no direct costs reported for the same period in 2024, attributed to the acquisitions of Myrtle and RCHI [235]. - Research and development expenses decreased to $30,000 for the three months ended March 31, 2025, from $165,360 in the same period of 2024, reflecting the cessation of ongoing projects [236]. - Selling, general and administrative expenses rose to $2.8 million for the three months ended March 31, 2025, compared to $1.0 million in 2024, primarily due to expenses from the acquired companies [238]. - The net loss attributable to FOXO was $0.6 million for the three months ended March 31, 2025, an improvement from a loss of $1.5 million in 2024, mainly due to a gain from extinguishment of Senior PIK Notes [243]. - The company recorded a gain of $1.9 million from the extinguishment of $5.4 million of Senior PIK Notes during the three months ended March 31, 2025 [240]. - Total revenues for the healthcare segment were $3.2 million for the three months ended March 31, 2025, with a segment loss of $0.8 million [245]. - Labs and Life segment revenues increased by 18.23% to $8,489 for the three months ended March 31, 2025, compared to $7,180 in 2024 [248]. Cash Flow and Capital - As of March 31, 2025, the company had cash and cash equivalents of $16,907, a decrease of $51,361 from $68,268 as of December 31, 2024 [266]. - For the three months ended March 31, 2025, the company incurred a net loss of $1.1 million, an improvement from a net loss of $2.2 million for the same period in 2024 [250]. - The working capital deficit improved to $25.5 million as of March 31, 2025, compared to $29.8 million as of December 31, 2024, reflecting a change of $4.4 million [266]. - Total debt, net of discounts, decreased to $6.0 million as of March 31, 2025, down from $10.2 million as of December 31, 2024, a reduction of $4.2 million [266]. - Net cash used in operating activities for the three months ended March 31, 2025, was $1.3 million, compared to $0.4 million for the same period in 2024, indicating an increase in cash used by $0.9 million [268]. - The company raised $1.3 million from financing activities during the three months ended March 31, 2025, compared to $0.4 million in the same period of 2024 [270]. - The company expects to incur additional losses in future periods and requires additional capital to fund its operations [250]. Revenue Recognition and Accounting - Estimated contractual allowances and implicit price concessions of $17.5 million were recorded as reductions to revenues for the three months ended March 31, 2025 [283]. - After accounting for estimated contractual allowances and implicit price concessions, the healthcare segment recorded net revenues of $3.2 million for the three months ended March 31, 2025 [283]. - The healthcare segment's primary source of operating cash is the collection of outstanding receivables, which is critical to its operating performance [281]. - The performance obligations for inpatient services are generally satisfied over periods averaging approximately 7 to 28 days, while outpatient services are satisfied in less than one day [278]. - The healthcare segment's revenues are based on estimated amounts expected to be received from third-party payers and patients, influenced by Medicare and Medicaid rates [279]. - The company does not present "allowances for doubtful accounts" on its balance sheets; accounts receivable are reported at realizable value, net of estimated contractual allowances [282]. - The company assesses going concern uncertainty quarterly, considering cash and working capital to operate for at least one year from the issuance date of consolidated financial statements [286]. Future Plans and Developments - The company entered into a KR8 Agreement to develop a Direct-to-Consumer APP utilizing AI Machine Learning technology, effective January 12, 2024 [231]. - The company plans to adopt ASU 2023-09 effective January 1, 2025, which requires enhanced annual disclosures for specific categories in income tax disclosures [287].

Core Insights - FOXO Technologies Inc. is expanding its critical access hospital, Big South Fork Medical Center, to include wound care services starting June 2, 2025 [1][3] - The expansion is driven by an increasing demand for wound care, particularly among diabetic patients, with over 38 million diabetes patients in the U.S. and up to 15% experiencing diabetic foot ulcers [2] - The hospital currently serves over 600 emergency room patients and approximately 300 outpatient patients monthly, indicating a strong community presence [3] Company Overview - FOXO operates three subsidiaries, including Rennova Community Health, which manages Big South Fork Medical Center, a critical access hospital in East Tennessee [4] - Myrtle Recovery Centers, another subsidiary, provides behavioral health services, including inpatient detox and outpatient treatment programs [4] - FOXO Labs focuses on biotechnology aimed at improving human health and lifespan through innovative technology and product solutions [5]

Core Insights - FOXO Technologies Inc. announced significant patient care milestones achieved by its subsidiary, Myrtle Recovery Centers, which has treated over 400 patients and provided more than 5,000 care days since opening in August 2023 [1][2] - Myrtle Recovery Centers aims to serve 10,000 patient care days by the end of 2025, indicating strong growth and demand for its services in East Tennessee [2] - FOXO Technologies is pleased with the operational ramp-up of Myrtle and plans to expand its footprint to meet increasing demand, which is expected to enhance revenue contributions from this subsidiary [2][3] Company Overview - FOXO Technologies operates three subsidiaries, including Myrtle Recovery Centers, which is a 30-bed behavioral health facility providing inpatient and outpatient services for substance use disorder [3] - The company also owns Rennova Community Health, which operates a critical access hospital in East Tennessee, and FOXO Labs, a biotechnology firm focused on health and lifespan improvement [3][4]

Core Viewpoint - FOXO Technologies Inc. has completed a 1 for 10 reverse stock split of its outstanding common stock, effective April 28, 2025, with trading resuming on a post-split basis on April 29, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split consolidates every 10 shares of common stock into one share, maintaining the nominal par value per share at $0.0001 [2]. - The number of shares will decrease from approximately 38.7 million to approximately 3.87 million post-split [3]. - All outstanding preferred shares, stock options, warrants, and equity incentive plans will be adjusted accordingly, with the number of shares divided by 10 and the exercise or conversion price multiplied by 10 [4]. Group 2: Administrative Aspects - Continental Stock Transfer & Trust Company has been retained as the exchange agent for the reverse stock split, providing instructions for stockholders of record [5]. - Stockholders with shares held through brokers will have their positions automatically adjusted without needing to take action [5]. - The reverse split was approved by the Company's directors on April 17, 2025, following a majority shareholder resolution on November 29, 2024 [6]. Group 3: Company Overview - FOXO Technologies Inc. operates three subsidiaries: Rennova Community Health, which owns Scott County Community Hospital, Myrtle Recovery Centers, a behavioral health facility, and Foxo Labs, a biotechnology company focused on health and lifespan improvement [7][8].